Overview

F 18 T807 Tau PET Imaging of Alzheimer's Disease

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This project will collect quantitative pilot data that will allow the characterization of uptake and binding of 18F-AV-1451 (also known as F 18 T807), a novel tau imaging compound, in individuals with and without brain tau fibrils. The primary goal is to develop tau imaging technique as an antecedent biomarker of cognitive decline. The investigators propose to obtain preliminary data that will support the possibility of detecting cognitive decline in its earliest stages, before the occurrence of dementia.
Details
Lead Sponsor:
Tammie L. S. Benzinger, MD, PhD
Washington University School of Medicine